Skip to main content

Endocrine Response to Heart Failure

  • Chapter
Acute Heart Failure

Part of the book series: Update in Intensive Care and Emergency Medicine ((UICM,volume 6))

Abstract

Cardiac failure is a clinical entity of various causes and severity characterized by an inability of the heart to deliver a sufficient amount of blood to meet the metabolic demands of the body at rest or during exercise. Thus, as acute or chronic heart failure develops, several compensatory mechanisms are activated to maintain an adequate perfusion to vital organs such as the brain and the heart, at the expense of other non-essential organs such as the kidneys, the gut or the muscles. The neurohumoral systems involved in the maintenance of blood pressure when heart function is failing are the same as those implicated in the regulation of blood pressure when dehydration or severe losses of blood volume occur i.e. the sympathetic nervous system, the renin-angiotensin-aldosterone system and plasma arginine vasopressin. This endocrine response results in various degrees of peripheral vasoconstriction and renal sodium retention depending on the severity of the cardiocirculatory imbalance. In advanced heart failure, however, the increase in peripheral resistance and the enhanced sodium reabsorption with subsequent volume expansion are likely to compromise myocardial function by increasing afterload as well as myocardial oxygen consumption. A vicious circle is established that will lead to further irreversible myocardial damage despite the activation of other systems with vasodilatory and natriuretic properties such as the atrial natriuretic peptide or the protaglandins. An integrated scheme demonstrating the neurohumoral consequences of heart failure is presented in Fig. 1.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Di Bona GF (1977) Neurogenic regulation of renal tubular sodium reabsorption. Am J Physiol 233: 173–181

    Google Scholar 

  2. Goldstein DS, McCarthy R, Polinsky RJ, Kopin IJ (1983) Relationship between plasma norepinephrine and sympathetic neural activity. Hypertension 5: 552–559

    PubMed  CAS  Google Scholar 

  3. Thomas JA, Marks BH (1978) Plasma norepinephrine in congestive heart failure. Am J Cardiol 41: 233–243

    Article  PubMed  CAS  Google Scholar 

  4. Levine TB, Francis GS, Goldsmith SR, Simon AB, Cohn JN (1982) Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relationship to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 49: 1659–1666

    Article  PubMed  CAS  Google Scholar 

  5. Gaffney TE, Braunwald E (1963) Importance of adrenergic nervous system in the support of circulatory function in patients with congestive heart failure. Am J Med 34: 320–324

    Article  PubMed  CAS  Google Scholar 

  6. Cohn JN, Levine TB, Olivari MT, et al (1984) Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311: 819–823

    Article  PubMed  CAS  Google Scholar 

  7. Chidsey CA, Braunwald E, Morrow AG (1965) Catecholamine excretion and cardiac stores of norepinephrine in congestive heart failure. Am J Med 39: 442–450

    Article  PubMed  CAS  Google Scholar 

  8. Dzau VJ, Hollenberg NK, Williams GH (1983) Neurohumoral mechanisms of heart failure: role in pathogenesis, therapy, and drug tolerance. Fed Proc 42: 3162–3169

    PubMed  CAS  Google Scholar 

  9. Bristow MR, Ginsburg R, Monibe W, et al (1982) Decreased catecholamine sensitivity and 1-adrenergic-receptor density in failing human heart. N Engl J Med 307: 205–211

    Article  PubMed  CAS  Google Scholar 

  10. Chidsey CA, Braunwald E, Morrow AG, Mason DT (1963) Myocardial norepinephrine concentration in man: Effects of reserpine and of congestive heart failure. N Engl J Med 269: 653–658

    Google Scholar 

  11. Pierpont GL, Francis GS, DeMaster EG, Levine TB, Bolman RM, Cohn JN (1983) Elevated left ventricular myocardial dopamine in preterminal idiopathic dilated cardiomyopathy. Am J Cardiol 52: 1033–1035

    Article  PubMed  CAS  Google Scholar 

  12. Chidsey CA, Harrison OL, Braunwald E (1962) Augmentation of the plasma norepinephrine response to exercise in patients with congestive heart failure. N Engl J Med 267: 650–654

    Article  PubMed  CAS  Google Scholar 

  13. Olivari MT, Levine TB, Cohn JN (1983) Abnormal neurohumoral response to nitroprusside infusion in congestive heart failure. J Am Coll Cardiol 2 (3): 411–417

    Article  PubMed  CAS  Google Scholar 

  14. Eckberg DL, Drabinsky M, Braunwald E (1971) Defective cardiac parasympathetic control in patients with heart disease. N Engl J Med 285: 877–883

    Article  PubMed  CAS  Google Scholar 

  15. Giles TD, Iteld BJ, Mautner RK, Rognoni PA, Dillenkoffer RL (1981) Short-term effects of intravenous clonidine in congestive heart failure. Clin Pharmacol Ther 30: 724–728

    Article  PubMed  CAS  Google Scholar 

  16. Francis GS, Parks R, Cohn JN (1983) The effects of bromocriptin in patient with congestive heart failure. Am Heart J 106: 100–106

    Article  PubMed  CAS  Google Scholar 

  17. Levine TB (1985) Role of vasodilators in the treatment of congestive heart failure. Am J Cardiol 55: 32A - 35A

    Article  PubMed  CAS  Google Scholar 

  18. Elkayam U, Le Jemtel TH, Mathur M, et al (1979) Marked early attenuation of hemodynamic effect of oral prazosin therapy in chronic congestive heart failure. Am J Cardiol 44: 540–545

    Article  PubMed  CAS  Google Scholar 

  19. Veterans Administration Cooperative Study (1986) Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med 314: 1547–1552

    Article  Google Scholar 

  20. Colucci WS, Williams GH, Braunwald E (1981) Clinical, hemodynamic and neuroendocrine effects of chronic prazosin therapy for congestive heart failure. Am Heart J 102: 615–621

    Article  PubMed  CAS  Google Scholar 

  21. Goldberg LI, Hsieh YY, Resnetov L (1977) Newer catecholamines for treatment of heart failure and shock: an update on dopamine and a first look at dobutamine. Progr Cardiovasc Dis 19 (4): 327–340

    Article  CAS  Google Scholar 

  22. Colucci WS, Alexander RW, Williams GH, et al (1981) Decreased lymphocyte ß-adrenergicreceptor density in patients with heart failure and tolerance to the ß-adrenergic agonist pirbuterol. N Engl J Med 305: 185–190

    Article  PubMed  CAS  Google Scholar 

  23. Rajfer SI, Anton AH, Rossen JD, Goldberg LI (1984) Beneficial hemodynamic effects of oral levodopa in heart failure. N Engl J Med 310: 1357–1362

    Article  PubMed  CAS  Google Scholar 

  24. Fisher ML, Plotnick GD, Peters RW, Carliner NH (1986) Beta-blockers in congestive cardiomypathy. Conceptual advance or contraindication. Am J Med 80 (Suppl 2B): 59–66

    Article  PubMed  CAS  Google Scholar 

  25. Packer M (1987) Converting enzyme inhibition in the management of severe chronic congestive heart failure: physiologic concepts. J Cardiovasc Pharmacol 10 (S7): S83 - S87

    Article  PubMed  Google Scholar 

  26. Deboben A, Inagami T, Ganten D (1983) Tissue renin. In: Genest J, Kuchel O, Hamet P, Cantin M (eds) Hypertension–physiopathology and treatment. McGraw-Hill, New York, pp 194–209

    Google Scholar 

  27. Gavras H, Kremer D, Brown JJ, et al (1975) Angiotensin-and norepinephrine-induced myocardial lesions: experimental and clinical studies in rabbits and man. Am Heart J 89 (3): 321–332

    Article  PubMed  CAS  Google Scholar 

  28. Turini GA, Brunner HR (1982) The role of hormones in congestive heart failure: new frontiers in therapy? Clin Sci 63: 333–338

    PubMed  CAS  Google Scholar 

  29. Turini GA, Waeber B, Brunner HR (1983) The renin-angiotensin system in refractory heart failure: clinical, hemodynamic and hormonal effects of captropril and enalapril. Eur Heart J 4 (Suppl A): 189–197

    PubMed  Google Scholar 

  30. Captopril Multicenter Research Group (1983) A pacebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol 2: 755–763

    Article  Google Scholar 

  31. The Consensus Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 23: 1429–1435

    Google Scholar 

  32. Fyhrquist F, Hortling L, Forslund T, Laasonen L (1982) Reduction of plasma vasopressin and renin substrate in congestive heart failure during captopril treatment. From principle to practice, Biomedical Information Co, New York pp 51–62

    Google Scholar 

  33. Szatalowicz VL, Arnold PE, Chaimovitz C, Bichet DG, Berl T, Schrier RW (1981) Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med 305: 263–266

    Article  PubMed  CAS  Google Scholar 

  34. Bichet DG, Kortas C, Mettauer B, et al (1986) Modulation of plasma and platelet vasopressin by cardiac function in patients with heart failure. Kidney Int 29: 1188–1196

    Article  PubMed  CAS  Google Scholar 

  35. Montani JP, Liard JF, Schoun J, Moehring JH (1980) Hemodynamic effect of exogenous and endogenous vasopressin at low concentrations in conscious dogs. Circ Res 47: 346–355

    PubMed  CAS  Google Scholar 

  36. Cowley AW, Monos E, Guyton AC (1974) Interaction of vasopressin and the baroreceptor reflex system in the regulation of arterial blood pressure in the dog. Circ Res 34: 505–514

    PubMed  CAS  Google Scholar 

  37. Goldsmith SR, Francis GS, Cowley AW, Goldenberg IF, Cohn JN (1986) Hemodynamic effects of infused arginine vasopressin in congestive heart failure. J Am Coll Cardiol 8: 779–783

    Article  PubMed  CAS  Google Scholar 

  38. Nicod P, Biollaz J, Waeber B, et al (1986) Hormonal, global and regional hemodynamic responses to a vascular antagonist of vasopressin in patients with congestive heart failure with and without hyponatremia. Br Heart J 56: 433–439

    Article  PubMed  CAS  Google Scholar 

  39. Edwards BS, Zimmerman RS, Burnett JC (1987) Atrial natriuretic factor: physiologic actions and implications in congestive heart failure. Cardiovasc Drugs Ther 1: 89–100

    Article  PubMed  CAS  Google Scholar 

  40. Biollaz J, Bidiville J, Diézi J, et al (1987) Site of the action of a synthetic atrial natriuretic peptide evaluated in humans. Kidney Int 32: 537–546

    Article  PubMed  CAS  Google Scholar 

  41. Cody RJ, Atlas SA, Laragh JH, et al (1986) Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal and hemodynamic responses to peptide infusion. J Clin Invest 78: 1362–1374

    Article  PubMed  CAS  Google Scholar 

  42. Goy JJ, Waeber B, Nussberger J, et al (1988) Infusion of atrial natriuretic peptide to patients with congestive heart failure. J Cardiovasc Pharmacol (In press)

    Google Scholar 

  43. Tsunoda K, Mandelsohn FAO, Sexton PM, Chai SY, Hodsman GP, Johnston CI (1988) Decreased atrial natriuretic peptide binding in renal medulla in rats with chronic heart failure. Circ Res 62: 155–161

    PubMed  CAS  Google Scholar 

  44. Mauer EF (1955) The toxic effects of phenylbutazone (butazolidin): review of the literature and report of the twenty-third death following its use. N Engl J Med 253: 404–410

    Article  PubMed  CAS  Google Scholar 

  45. Dzau VJ, Packer M, Lilly LS, Swartz SL, Hollenberg NK, Williams GH (1984) Prostaglandins in severe congestive heart failure. Relation to activation of the renin-angiotensin system and hyponatremia. N Engl J Med 310: 347–352

    Google Scholar 

  46. Liang CS, Imai N, Stone CK, Woolf PD, Kawashima S, Tuttle RR (1987) The role of endogenous opioids in congestive heart failure: effects of nalamefene on systemic and regional hemodynamic in dogs. Circulation 75 (2): 443–451

    Article  PubMed  CAS  Google Scholar 

  47. Archelos J, Xiang JZ, Lang RE (1987) Regulation of release and function of neuropeptides in the heart. J Cardiovasc Pharmacol 10 (Suppl 12): S45 - S50

    Article  PubMed  CAS  Google Scholar 

  48. Waeber B, Aubert JF, Corder R, et al (1988) Cardiovascular effects of neuropeptide Y. Am J Hypertension (In press)

    Google Scholar 

  49. Lee WH, Packer M (1986) Congestive heart failure: Prognostic importance of serum sodium concentration and its modification by converting enzyme inhibition in patients with severe chronic heart failure. Circulation 73: 257–267

    Google Scholar 

Download references

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1988 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Burnier, M., Waeber, B., Nussberger, J., Brunner, H.R. (1988). Endocrine Response to Heart Failure. In: Perret, C., Vincent, J.L. (eds) Acute Heart Failure. Update in Intensive Care and Emergency Medicine, vol 6. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-83453-0_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-83453-0_8

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-19169-8

  • Online ISBN: 978-3-642-83453-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics